Cell Therapy News/Articles, page-13258

So the FDA have shown this week that they are obviously still interested in MSC’s as a treatment for COVID-19 ARDS (regardless of some on here trying to claim otherwise) through their BioCardia IND approval and yet we still wait for Mesoblast and we assume the NIH to get started on the additional phase 3 Remestemcel-L trial for COVID-19 ARDS ?

After reading the Nature article below containing reporting from the Lancet it really is disappointing that our additional trial hasn’t started yet ? Maybe Mesoblast are waiting for the 12 month data; maybe they are not but I think they have had ample time to get things organised including funding by a third party - just sayin’ !


https://eresearch.fidelity.com/eres...ovider=BENZINGA&product=FULLNGTH&sb=1
FDA Approves BioCardia's Phase 1 Trial With Cell Therapy In COVID-19, Shares Jump




https://www.nature.com/articles/d41586-022-00708-0
COVID’s true death toll: much higher than official records


Modelling suggests that by the end of 2021, some 18 million people had died because of the pandemic.

The number of people who have died because of the COVID-19 pandemic could be roughly three times higher than official figures suggest, according to a new analysis¹.

The study, published on 10 March in The Lancet, says that the true number of lives lost to the pandemic by 31 December 2021 was close to 18 million. That far outstrips the 5.9 million deaths that the study says were reported to various official sources for the same period. The difference is down to significant undercounts in official statistics, owing to delayed and incomplete reporting and a lack of data in dozens of countries.

The loss of life “is much higher than simply assessed by reported COVID-19 deaths in most countries”, says study co-author Haidong Wang, a demographer and population-health expert at the Institute for Health Metrics and Evaluation (IHME) in Seattle, Washington. “Understanding the true death toll from the pandemic is vital for effective public health decision-making.”